CD44 and prostate carcinoma: We conducted experiments to characterize the relationship between CD44 and integrin subunit expression and/or activation, using two representative CD44-expressing models of BLBC, the MDA-MB-231 and Hs578T cell lines [6], and the metastatic prostate cancer cell line, PC3 [10].